Cancer drug futibatinib gets a safety check in Long-Term rollover study
NCT ID NCT06506955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Only 15 participants are expected, and the study is open-label, meaning everyone knows what treatment they are getting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
futibatinib (alone or with fulvestrant)
What this could lead to
If successful, this study could show that long-term futibatinib treatment is safe and continues to control advanced cancer in patients who already responded.
What could go wrong
This is a very small rollover study (15 patients) with no control group, so results may not apply broadly. Side effects from long-term use are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Integral Oncologico
Madrid, 28050, Spain
-
Hospital Universitari, Vall d'Hebron
Barcelona, 8035, Spain
-
Institut De Cancerologie Strasbourg
Strasbourg, 67033, France
-
Institut Paoli-Calmettes
Marseille, 13009, France
-
Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
Sarah Cannon Research Institute UK
London, W1G 6AD, United Kingdom
-
Severance Hospital
Seoul, 3722, South Korea
-
University College London Hospitals NHS Foundation Trust
London, W1T 7HA, United Kingdom
-
University of California, San Francisco (UCSF)
San Francisco, California, 94143, United States